Health Care Technology

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) will begin implementing Abbott's STARLIMS® software-based laboratory information management system (LIMS) as part of the agency's initiative to enhance FDA testing laboratories. STARLIMS LIMS software will be...

MGT Capital Investments, Inc. (NYSE: MGT) announced today that NYSE Amex, LLC has accepted the Company's plan of compliance submitted in response to a notice from the Exchange Staff dated June 8, 2011 indicating that the Company was not in compliance with certain continued listing standards as set...

HealthStream, Inc. (NASDAQ: HSTM) announced today that J. Edward Pearson, senior vice president, has been promoted to senior vice president & chief operating officer, effective immediately, and Kevin P. O'Hara, senior vice president & general counsel, has resigned, effective September 16,...

Omnicell, Inc . (NASDAQ: OMCL), today announced a joint partnership with Premier Purchasing Partners, L.P., the group purchasing unit of Premier Inc. The 36-month agreement allows Premier member hospitals and healthcare organizations to take advantage of premium pricing for the comprehensive suite...

MedAssets, Inc. (NASDAQ: MDAS) today announced that its Board of Directors has authorized the repurchase of up to $25 million of the company's Common Stock. The company also announced that it made a $25 million voluntary prepayment on its outstanding term loan in August.

MGT Capital Investments, Inc. (NYSE: MGT) is providing the following update on recent developments at the Company and its majority-owned subsidiary Medicsight PLC. In addition, MGT is reporting a summary of its recently filed financial results (via SEC Form 10-Q on August 15, 2011) for the period...

Auriga has published a research report on MedAssets (NASDAQ: MDAS) lowering Price Target, but reiterating the BUY rating. In the report, Auriga wrote, "We are making some modest downward adjustments to our FY12 estimates for revenue, EBITDA and EPS as we take a more conservative approach to top-...

Auriga has lowered the price target on MedAssets (NASDAQ: MDAS) from $21 to $19 and maintains its Buy rating.

Impax Laboratories (NASDAQ: IPXl) +10.54% after announcing positive topline results of ASCEND-PD phase III study of IPX066 in advanced Parkinson's disease. Cathay General Bancorp (NASDAQ: CATY) +11.21% - hearing that the company was upgraded to Outperform at RBC Capital Markets. Green Dot...

TRANSCEND SERVICES, INC. (NASDAQ: TRCR) today announced that it has entered into a new agreement with Multimodal Technologies, Inc. (“M*Modal”) under which M*Modal will continue to provide Speech Understanding technology to Transcend. The new agreement, which amends a 2006 agreement, has an...

Oppenheimer reiterated its Outperform rating on MedAssets (NASDAQ: MDAS). At the same time, the rating agency left its price target on the company's stock unchanged at $20. In today's trading, MDAS lost 0.25% of its value to stand around $12.07.

Trimble Navigation Limited (NASDAQ: TRMB) +13.54% on the upbeat earning reported yesterday. j2 Global Communications, Inc. (NASDAQ: JCOM) +16.59% on the upbeat earning reported yesterday. Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) +11.83% on several analyst upgrades this morning. Quanta...

Auriga has upgraded Allscripts (NASDAQ: MDRX) from Hold to Buy and has established a $22 price target.

Morgan Keegan has lowered its price target on Allscripts Healthcare Solutions (NASDAQ: MDRX) from $27 to $24 but is maintaining its Outperform rating on the stock. In its report, Morgan Keegan states, “MDRX has a huge physician billing software footprint that it should leverage as the government...

According to Piper Jaffray, Allscripts (NASDAQ: MDRX) is upgraded to Overweight. Piper Jaffray said that it is maintaining its $22 price target after the company reported Q2 earnings ahead of expectations. “We believe much of the integration risk from the Eclipsys merger is behind the company, or...